Alpha-1 Antitrypsin Genotyping MSAC Submission
Click here for Lung Foundation Australia’s submission to MSAC to list Alpha-1 Antitrypsin Genotyping on the Medicare Benefits Schedule.
Click here for Lung Foundation Australia’s submission to MSAC to list Alpha-1 Antitrypsin Genotyping on the Medicare Benefits Schedule.
Click here to read results of a patient survey conducted into streamlining pathology testing for Alpha1 Antitrypsin.
Click here to access our submission to the federal government inquiry into the COVID-19 pandemic.
Click here to learn more about what Lung Cancer Screening in Australia could look like.
Click here for Lung Foundation Australia’s submission of the National Strategic Action plan for Occupational Dust diseases for the Dust Diseases Taskforce.
Click here for the DOS and DONTS of writing consumer comments for PBAC submissions.
Click here for a tip sheet for submitting consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC).
The financial statements to accompany Lung Foundation Australia’s Annual Report of 2019.
Lung Foundation Australia’s 2019 Annual Research Impact Report feature the key research highlights of 2019.
Lung Foundation Australia’s 2019 Annual Impact Report featuring the key highlights of 2019.